A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemo… (NCT01881282) | Clinical Trial Compass
CompletedPhase 4
A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids
China123 participantsStarted 2006-12-14
Plain-language summary
The purpose of this study is to compare the therapeutic effect and safety of compound carraghenates cream with Mayinglong musk hemorrhoid (swollen veins in the lower part of the rectum or anus) ointment in the treatment of hemorrhoids, especially regarding the relief of pain.
Who can participate
Age range
16 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants who agree to participate in the current study
* Participants having painful hemorrhoids (swollen veins in the lower part of the rectum or anus \[external hemorrhoid, mixed hemorrhoid, etc.\])
* Participants who did not use other topical drugs to treat their hemorrhoids a day before the inclusion
* Participants who do not use drugs other than the study drug and the control drug to treat their hemorrhoids during the study period
Exclusion Criteria:
* Participants having other anorectal diseases , such as anal fistula , anal cleft , perianal abscess , and anorectal occupied lesions etc
* Participants having hypersensitive predisposition or hypersensitive to any of components of the study drugs
* Female participants under pregnancy or during breastfeeding period
* Participants who fail to accept the scheduled visits or are lost to the visits
* Participants complicated by serious cardio cerebro vascular diseases, hepatic and renal diseases, diseases of hemopoietic system or mental disorders
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Pain Acting Time
Timeframe: Day 1 up to Day 7
2
Pain Intensity Score at Day 4
Timeframe: Day 4
3
Pain Intensity Score at Day 7
Timeframe: Day 7
4
Daily Duration of Symptoms
Timeframe: Day 1 up to Day 7
5
Frequency of Defecation
Timeframe: Day 1 up to Day 7
6
Participants' Satisfaction for the Treatment
Timeframe: Day 7
7
Assessment of Other Symptoms and Signs Including Bleeding, Edema, Local Discomfort, and Prolapse